The silence in the clinic at Dr. George Mukhari Academic Hospital in Pretoria used to be heavy, defined by the wince of patients enduring the excruciating daily injections that were the standard of care for drug-resistant tuberculosis. Today, that silence has been replaced by the sound of rapid recovery. At the center of this medical revolution stands Dr. Norbert Ndjeka, a man whose life is uniquely tied to the disease he spent his career dismantling—he was born on World Tuberculosis Day.

For decades, treating drug-resistant tuberculosis (DR-TB) in South Africa was akin to a war of attrition. Patients were tethered to clinics for nearly two years, subjected to daily injections that caused irreversible hearing loss and profound psychological trauma. As the Chief Director of TB Control and Management at South Africa’s National Department of Health, Ndjeka recognized that the greatest barrier to curing the disease was not the bacteria itself, but the treatment regimen that patients could not survive, let alone tolerate. Under his stewardship, South Africa became the first country globally to aggressively transition to all-oral, shorter treatment regimens, fundamentally altering the trajectory of the epidemic.

The End of the Injection Era

The traditional treatment protocol for multi-drug resistant tuberculosis (MDR-TB) was a brutal ordeal. Until recent years, the standard regimen required patients to undergo up to 20 months of therapy, including at least six months of daily, painful injections. The side effects were often as debilitating as the illness. Thousands of patients suffered from permanent tinnitus or total deafness, a devastating price to pay for survival. The dropout rate was catastrophic patients often fled treatment before completion because the "cure" felt like a slow destruction of their quality of life.

Ndjeka championed the move toward the BPaL/M regimen—a breakthrough combination of drugs that includes bedaquiline, pretomanid, and linezolid, sometimes paired with moxifloxacin. This shift reduced treatment duration from 20 months to as little as six months. The clinical impact was immediate and measurable:

• Treatment success rates for DR-TB in South Africa climbed from below 50 percent to over 85 percent in treated cohorts.
• The elimination of injectable agents saved thousands of patients from drug-induced deafness and chronic pain.
• Operational costs per patient dropped significantly, with shortened treatment cycles reducing the burden on inpatient facilities by an estimated 60 percent.
• Public health savings are projected in the billions of Rand, allowing for resource reallocation toward active case finding.

Data and Dignity in Treatment

The scientific rigor brought to the department by Ndjeka allowed South Africa to bypass bureaucratic inertia. By leveraging data from early clinical trials and coordinating with global partners like the World Health Organization, he pushed for the rapid scale-up of bedaquiline. This was not merely an administrative choice it was an ethical imperative. The cost-effectiveness of this transition is staggering. While the drugs themselves initially carried a premium price, the reduction in hospitalization days—which cost the South African public health system thousands of Rand daily—resulted in a net positive economic impact.

For a patient, the transition meant the difference between a life of isolation and a return to employment. Consider the case of a former miner in the North West province who had been treated for two years with no success. Under the new oral regimen, he tested negative for TB within three months. This personal victory, multiplied by thousands across the country, represents the successful dismantling of a public health disaster.

The Kenya-South Africa Nexus

This medical breakthrough carries profound implications for Nairobi and the wider East African region. Kenya, classified by the World Health Organization as a high-burden country for tuberculosis, has closely observed the South African model. The Kenyan National Tuberculosis, Leprosy and Lung Disease Program (NTLD-P) has increasingly adopted similar all-oral regimens, though implementation challenges—such as drug supply chain logistics and the need for decentralized diagnostic services—persist.

The cost disparity remains a primary concern for Kenyan policymakers. In South Africa, the scale of procurement has allowed for aggressive price negotiations with pharmaceutical manufacturers. In contrast, Kenyan health officials are tasked with navigating more fragmented procurement pathways. However, the logic remains the same: the cost of a six-month course of oral medication is KES 65,000 (roughly $500) per patient, whereas the societal and long-term healthcare costs of untreated or improperly treated DR-TB can exceed KES 1.3 million (approximately $10,000) when accounting for hospital stays, disability support, and loss of productivity.

A Legacy Written in Resilience

Critics of rapid drug adoption often point to the risk of acquired resistance if drugs are used improperly. Ndjeka has consistently argued that the risk of doing nothing—of keeping patients on older, less effective drugs—far outweighs the risks of implementation. His strategy emphasized rigorous patient monitoring and community-based support, ensuring that the short-course regimen was not just distributed but correctly administered. This focus on "patient-centered care" has become the blueprint for other developing nations seeking to end the TB epidemic by 2030.

As South Africa moves forward, the focus is now shifting to active case finding—the hunt for the "missing" patients who are undiagnosed in the community. The battle against TB is evolving from a reactionary struggle of containment to a proactive campaign of eradication. For the boy born on World TB Day, the mission has been to ensure that the disease, which once defined the lives of his fellow citizens, eventually becomes a footnote in the country’s medical history.

The path forward is clear: the technology exists, the regimens are proven, and the political will in South Africa has been solidified. The question now for neighboring nations is not whether they can afford to shift to shorter, all-oral treatment, but whether they can afford to wait.